Subsidy Program Could Potentially Impact Clinical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

To embed, copy and paste the code into your website or blog:
In Advisory Opinion No. 20-05, posted September 23, 2020, OIG was unwilling to approve a pharmaceutical company s proposed cost-sharing subsidy program for beneficiaries seeking to use its expensive new drug for treatment of a rare cardiovascular disease. While OIG stated it was not in a position to reach a definitive conclusion regarding whether a violation of the federal Anti-Kickback Statute (AKS) existed, OIG was unwilling to issue a favorable advisory opinion. In particular, OIG was concerned that the arrangement would make beneficiaries less sensitive to the costs of their treatment, thereby risking an increase in the costs to the federal health care programs, and influencing clinical and beneficiary decision-making. Notably, OIG highlighted its use of publicly available information in reaching its conclusion under the AKS. With respect to the beneficiary inducement statute, OIG found the proposed arrangement d ....

United States , Baker Ober Health Law , Subsidy Program , Subsidy Program May Decrease Fair Competition , Subsidy Program Could Potentially Impact Clinical Decision , Baker Ober Health , Advisory Opinion , Anti Kickback Statute , Proposed Arrangement , Cost Sharing Subsidy , Medicare Low Income , Publicly Available Information Influences , Medicare Low Income Subsidy , Beneficiary Inducements , Plain Language , Subsidy Card , Economic Safeguards That Keep , Medicare Program , Subsidy Program May Decrease Fair , Subsidy Program Could Potentially Impact Clinical , Beneficiary Inducement , ஒன்றுபட்டது மாநிலங்களில் , ரொட்டி சுடுபவர் ஒபர் ஆரோக்கியம் சட்டம் , மானியம் ப்ரோக்ர்யாம் , ரொட்டி சுடுபவர் ஒபர் ஆரோக்கியம் , ப்ரபோஸ்ட் ஏற்பாடு ,